* Sutro Biopharma Inc reported a quarterly adjusted loss of 95 cents per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of -85 cents. The mean expectation of ten analysts for the quarter was for a loss of 92 cents per share. Wall Street expected results to range from $-1.09 to -72 cents per share.
* Revenue rose 2.6% to $13.01 million from a year ago; analysts expected $12.07 million.
* Sutro Biopharma Inc's reported EPS for the quarter was a loss of 95 cents.
* The company reported a quarterly loss of $58.21 million.
* Sutro Biopharma Inc shares had fallen by 26.5% this quarter and lost 3.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 7.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Sutro Biopharma Inc is $12.00 This summary was machine generated from LSEG data May 13 at 10:22 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.92 -0.95 Missed
Dec. 31 2023 -0.82 0.52 Beat
Sep. 30 2023 -0.74 -0.81 Missed
Jun. 30 2023 -0.73 -0.64 Beat
Comments